LIPWAY SR Fenofibrate 250mg Sustained Release Capsule 1's
RXDRUG-DR-XY28840-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Lipway: Adults Only.
For the treatment of hyperlipidemias of type IIa, IIb, III, IV and V in patients who have not responded adequately to diet and other appropriate measures.
It is indispensable to continue the diet in all cases.
No long term controlled trials showing the efficacy of fenofibrate in the primary or secondary prevention of complications of atherosclerosis are available to date.
For the treatment of hyperlipidemias of type IIa, IIb, III, IV and V in patients who have not responded adequately to diet and other appropriate measures.
It is indispensable to continue the diet in all cases.
No long term controlled trials showing the efficacy of fenofibrate in the primary or secondary prevention of complications of atherosclerosis are available to date.
Dosage/Direction for Use
Lipway: In combination with diet, this drug constitutes a long-term symptomatic treatment, the efficacy of which should be assessed regularly.
Adults: For the management of primary hypercholesterolemic or mixed dyslipidemia: The recommended initial dosage of fenofibrate is 160 mg daily.
For the management of elevated serum triglyceride concentrations: The recommended initial dosage of fenofibrate in adults is 54-160 mg daily.
Dosage should be adjusted at intervals of 4-8 weeks until the desired effect on lipoprotein concentrations is observed or a maximum dosage of 160 mg daily.
Fenofibrate should be discontinued in patients who fail to achieve an adequate response after 2-3 months of therapy with the maximum recommended dosage of 160 mg daily.
Tablets should be swallowed whole during a meal.
Special Populations: The recommended initial dosage of fenofibrate for the management of hyperlipoproteinuria in patients 65 years of age or older and in those with renal impairment (creatinine clearance less than 50 mL/minute) is 54 mg daily. Dosage should be adjusted only after evaluating therapeutic response and the effects of the drug on renal function.
Adults: For the management of primary hypercholesterolemic or mixed dyslipidemia: The recommended initial dosage of fenofibrate is 160 mg daily.
For the management of elevated serum triglyceride concentrations: The recommended initial dosage of fenofibrate in adults is 54-160 mg daily.
Dosage should be adjusted at intervals of 4-8 weeks until the desired effect on lipoprotein concentrations is observed or a maximum dosage of 160 mg daily.
Fenofibrate should be discontinued in patients who fail to achieve an adequate response after 2-3 months of therapy with the maximum recommended dosage of 160 mg daily.
Tablets should be swallowed whole during a meal.
Special Populations: The recommended initial dosage of fenofibrate for the management of hyperlipoproteinuria in patients 65 years of age or older and in those with renal impairment (creatinine clearance less than 50 mL/minute) is 54 mg daily. Dosage should be adjusted only after evaluating therapeutic response and the effects of the drug on renal function.
Overdosage
Lipway: Symptomatic treatment.
Administration
Should be taken with food.
Contraindications
Lipway: Absolute Contraindications: Severe renal or hepatic impairment (see Precautions); Existing gallbladder disease; Pregnancy and breast feeding; Photosensitivity; Use in children.
Relative Contraindications: HMG CoA reductase inhibitors; Other fibrates (see Interactions).
Relative Contraindications: HMG CoA reductase inhibitors; Other fibrates (see Interactions).
Special Precautions
Lipway: Special warnings: There have been report of muscle damage, including exceptional cases of rhabdomyolysis, with fibrates. This may occur more frequently in patients with hypoalbuminaemia.
Muscle damage should be suspected in any patient who has diffuse myalgia, painful muscular sensitivity and/or major elevation of muscular CPK (5 times the normal level), in this situation the treatment should be discontinued.
Moreover, the risk of muscle damage may be increased if the drug is administered in combination with another fibrate or with an HMG CoA reductase inhibitor (see Interactions).
Precautions for use: If a satisfactory reduction of serum lipid concentrations has not been obtained after a period of administration of several months (3 to 6 months), additional or different therapeutic measures should be considered.
Elevation, generally transient, of transaminase levels have been observed in some patients. On the basis of current knowledge, this would appear to justify the following measures: Liver function tests recommended every 3 months for the first year (discontinue treatment if significantly raised).
Discontinuation of the treatment if ASAT and ALAT concentrations increase to over 3 times the upper normal limit.
If the patient is receiving concomitant oral anticoagulant treatment, closer monitoring of prothrombin time, as expressed by the INR, is essential (see Interactions).
Effects On The Ability To Drive And Use Machines: Not applicable.
Muscle damage should be suspected in any patient who has diffuse myalgia, painful muscular sensitivity and/or major elevation of muscular CPK (5 times the normal level), in this situation the treatment should be discontinued.
Moreover, the risk of muscle damage may be increased if the drug is administered in combination with another fibrate or with an HMG CoA reductase inhibitor (see Interactions).
Precautions for use: If a satisfactory reduction of serum lipid concentrations has not been obtained after a period of administration of several months (3 to 6 months), additional or different therapeutic measures should be considered.
Elevation, generally transient, of transaminase levels have been observed in some patients. On the basis of current knowledge, this would appear to justify the following measures: Liver function tests recommended every 3 months for the first year (discontinue treatment if significantly raised).
Discontinuation of the treatment if ASAT and ALAT concentrations increase to over 3 times the upper normal limit.
If the patient is receiving concomitant oral anticoagulant treatment, closer monitoring of prothrombin time, as expressed by the INR, is essential (see Interactions).
Effects On The Ability To Drive And Use Machines: Not applicable.
Use In Pregnancy & Lactation
Lipway: Pregnancy: The results of animal studies have shown no evidence of teratogenic effect. In man, no malformations or foetotoxic effects have been observed to date. However, the experience of pregnancies exposed to fenofibrate is insufficient to rule out any risk. There is no indication of prescribing fibrates during pregnancy, with the exception of major hypertriglyceridaemia (>10 g/L) insufficiently corrected by diet, which exposes the mother to the risk of acute pancreatitis.
Lactation: In the absence of information on the possible excretion of fenofibrate in breast milk, use of the product during lactation is not recommended.
Lactation: In the absence of information on the possible excretion of fenofibrate in breast milk, use of the product during lactation is not recommended.
Adverse Reactions
Lipway: Cases of muscle damage (diffuse myalgia, painful sensitivity, weakness) and exceptional cases of rhabdomyolysis, occasionally severe, have been reported as with other fibrates. They are generally reversible upon withdrawal of the treatment (see Precautions).
Other undesirable effects of moderate intensity have also been reported infrequently: Digestive (gastric or intestinal) disorders of the dyspeptic type; Elevation of transaminase levels (see Precautions); Hepatitis; Photosensitivity; Allergic skin reactions including rashes.
In the absence of sufficiently long experience and of controlled clinical studies, it is not at present possible to make a general estimation of undesirable effects in the long term and more particularly of the risk of biliary lithiasis.
Other undesirable effects of moderate intensity have also been reported infrequently: Digestive (gastric or intestinal) disorders of the dyspeptic type; Elevation of transaminase levels (see Precautions); Hepatitis; Photosensitivity; Allergic skin reactions including rashes.
In the absence of sufficiently long experience and of controlled clinical studies, it is not at present possible to make a general estimation of undesirable effects in the long term and more particularly of the risk of biliary lithiasis.
Drug Interactions
Lipway: Inadvisable Combinations: Other fibrates, HMG CoA reductase inhibitors: risk of additive undesirable muscular effects.
Combination requiring precautions: Oral anticoagulants increased effect of oral anticoagulants and greater risk of haemorrhage (through displacement of their plasma protein binding).
The INR should be monitored more frequently and the dosage of oral anticoagulants adjusted during and for 8 days after withdrawal of the treatment of with fenofibrate. The same of supervision is indispensable when switching to another fibrate, as the degree of potentiation is variable from one product to another.
Combination requiring precautions: Oral anticoagulants increased effect of oral anticoagulants and greater risk of haemorrhage (through displacement of their plasma protein binding).
The INR should be monitored more frequently and the dosage of oral anticoagulants adjusted during and for 8 days after withdrawal of the treatment of with fenofibrate. The same of supervision is indispensable when switching to another fibrate, as the degree of potentiation is variable from one product to another.
Storage
Store at temperatures not exceeding 30°C.
Action
Lipway: Pharmacology: Pharmacodynamics: Fenofibrate is a hypolipidaemic agent of the fibrate class, which inhibits the synthesis of cholesterol and triglycerides.
Fenofibrate can lower blood cholesterol levels by 20 to 25% and blood triglyceride levels by 40 to 50%.
The decrease in the cholesterol level is due to a reduction of the low density atherogenic fractions (VLDL and LDL). It improves the distribution of plasma cholesterol by reducing the total cholesterol: HDL cholesterol ratio, which increases in atherogenic hyperlipidaemia.
A relationship has been established between hyperlipidaemia and atherosclerosis and between atherosclerosis and cardiovascular morbidity. Low HDL levels are associated with an increased risk of coronary disease. High triglyceride levels are associated with an increased vascular risk, but it has not been established that this relation is independent. Moreover, triglycerides may be involved in the process of atherogenesis and also of thrombogenesis.
Extravascular deposits of cholesterol (xanthoma tendinosum and tuberosum) may regress considerably or even disappear completely with prolonged treatment.
A Uricosuric effect has been demonstrated in hyperlipidaemic patients, with resultant mean reduction of blood uric acid of about 25%.
With fenofibrate treatment, an increase in apoproteins A1 and a decease in apoproteins B improve the apoprotein A1:apoprotein B ratio, which can be regarded as a marker of the risk of atherogenesis.
An inhibitory effect of fenofibrate on platelet aggregation has been demonstrated in animals, and subsequently in man, in the course of clinical trial, it is manifested in reduction of aggregation induced by ADP, arachidonic acid and adrenaline.
In rats treated with fenofibrate, 80% inhibition of hepatic microsomal HMG CoA activity has been observed. This phenomenon may explain the mechanism of action of fenofibrate in man.
The sustained release form makes it possible to maintain effective plasma concentrations for longer periods.
Pharmacokinetics: Absorption: The product is not found in unchanged form in the plasma. The major metabolite in the plasma is fenofibric acid. Fenofibric acid is strongly bound to plasma albumin and may displace oral anticoagulants from the protein binding sites and potentiate their anticoagulant effect.
Fenofibrate is readily absorbed from the gastrointestinal tract when taken with food; absorption may be reduced if fenofibrate is given on an empty stomach.
Plasma half-life: Fenofibrate is rapidly hydrolysed to its active metabolite fenofibric acid which is about 99% bound to plasma albumin. The plasma elimination half-life of fenofibric acid is about 20 hours.
Metabolism and excretion: The product is eliminated essentially by the urinary route: 70% in 24 hours, 88% in 6 days, when the amount excreted attains 93% (urine and faeces). Fenofibrate is excreted principally as fenofibric acid and its glucuronide derivative. It is not removed by haemodialysis.
Fenofibrate can lower blood cholesterol levels by 20 to 25% and blood triglyceride levels by 40 to 50%.
The decrease in the cholesterol level is due to a reduction of the low density atherogenic fractions (VLDL and LDL). It improves the distribution of plasma cholesterol by reducing the total cholesterol: HDL cholesterol ratio, which increases in atherogenic hyperlipidaemia.
A relationship has been established between hyperlipidaemia and atherosclerosis and between atherosclerosis and cardiovascular morbidity. Low HDL levels are associated with an increased risk of coronary disease. High triglyceride levels are associated with an increased vascular risk, but it has not been established that this relation is independent. Moreover, triglycerides may be involved in the process of atherogenesis and also of thrombogenesis.
Extravascular deposits of cholesterol (xanthoma tendinosum and tuberosum) may regress considerably or even disappear completely with prolonged treatment.
A Uricosuric effect has been demonstrated in hyperlipidaemic patients, with resultant mean reduction of blood uric acid of about 25%.
With fenofibrate treatment, an increase in apoproteins A1 and a decease in apoproteins B improve the apoprotein A1:apoprotein B ratio, which can be regarded as a marker of the risk of atherogenesis.
An inhibitory effect of fenofibrate on platelet aggregation has been demonstrated in animals, and subsequently in man, in the course of clinical trial, it is manifested in reduction of aggregation induced by ADP, arachidonic acid and adrenaline.
In rats treated with fenofibrate, 80% inhibition of hepatic microsomal HMG CoA activity has been observed. This phenomenon may explain the mechanism of action of fenofibrate in man.
The sustained release form makes it possible to maintain effective plasma concentrations for longer periods.
Pharmacokinetics: Absorption: The product is not found in unchanged form in the plasma. The major metabolite in the plasma is fenofibric acid. Fenofibric acid is strongly bound to plasma albumin and may displace oral anticoagulants from the protein binding sites and potentiate their anticoagulant effect.
Fenofibrate is readily absorbed from the gastrointestinal tract when taken with food; absorption may be reduced if fenofibrate is given on an empty stomach.
Plasma half-life: Fenofibrate is rapidly hydrolysed to its active metabolite fenofibric acid which is about 99% bound to plasma albumin. The plasma elimination half-life of fenofibric acid is about 20 hours.
Metabolism and excretion: The product is eliminated essentially by the urinary route: 70% in 24 hours, 88% in 6 days, when the amount excreted attains 93% (urine and faeces). Fenofibrate is excreted principally as fenofibric acid and its glucuronide derivative. It is not removed by haemodialysis.
MedsGo Class
Dyslipidaemic Agents
Features
Brand
Lipway SR
Full Details
Dosage Strength
250 mg
Drug Ingredients
- Fenofibrate
Drug Packaging
Sustained Release Capsule 1's
Generic Name
Fenofibrate
Dosage Form
Sustained Release Capsule
Registration Number
DR-XY28840
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply